Gangtok Chronicle

DelveInsight Business Research LLP

DelveInsight’s “Progressive Pulmonary Fibrosis Interstitial Lung Disease Market Insights, Epidemiology, and Market Forecast-2032“ report delivers an in-depth understanding of the Progressive Pulmonary Fibrosis Interstitial Lung Disease, historical and forecasted epidemiology as well as the Progressive Pulmonary Fibrosis Interstitial Lung Disease market trends in the United States, EU4  (Germany, Spain, Italy, France, and the United Kingdom) and Japan.

The Progressive Pulmonary Fibrosis Interstitial Lung Disease market report provides current treatment practices, emerging drugs, Progressive Pulmonary Fibrosis Interstitial Lung Disease market share of the individual therapies, current and forecasted Progressive Pulmonary Fibrosis Interstitial Lung Disease market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current Progressive Pulmonary Fibrosis Interstitial Lung Disease treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Progressive Pulmonary Fibrosis Interstitial Lung Disease market.

 Some of the Key Facts of the Progressive Pulmonary Fibrosis Interstitial Lung Disease Market  Market Report:

• The US showed 175,660 diagnosed prevalent cases of Idiopathic Interstitial Pneumonia (IIPs). Furthermore, Autoimmune ILDs, Hypersensitivity Pneumonitis, Sarcoidosis and other ILDs cases were  119,420; 11,148; 148,098; and 32,887 respectively. 

• These types contribute to the Progressive form of Interstitial Lung Disease through applied progression rate in each sub-types of these classes.

• The United States showed the most diagnosed prevalent cases of PPF in the 7MM countries. In 2021, the total diagnosed prevalent cases of PPF in the US were 71,657 cases which is expected to rise by 2032.

Key Benefits of the Progressive Pulmonary Fibrosis Interstitial Lung Disease Market Report:

• The report covers the descriptive overview of Progressive pulmonary fibrosis (PPF), explaining its signs and symptoms, causes, classification, and currently available therapies.

• Comprehensive insight has been provided into the Progressive pulmonary fibrosis (PPF) epidemiology and treatment.

• Additionally, an all-inclusive account of both the current and emerging therapies for Progressive pulmonary fibrosis (PPF) is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.

• A detailed review of the Progressive pulmonary fibrosis (PPF) market; historical and forecasted is included in the report, covering the 7MM drug outreach.

• The report provides an edge while developing business strategies, by understanding trends shaping and driving the 7MM Progressive pulmonary fibrosis (PPF) market.

Got queries? Click here to know more about the Progressive Pulmonary Fibrosis Interstitial Lung Disease Market Landscape

Progressive Pulmonary Fibrosis Interstitial Lung Disease Overview

Progressive pulmonary fibrosis (PPF), also referred as progressive fibrosing interstitial lung disease (PF-ILD), defines the continuing worsening of any preexisting ILD of known or unknown etiology despite appropriate treatment. Interstitial lung disease is believed to be caused by long-term exposure to hazardous materials, such as asbestos or coal dust, or it can be caused by an auto-immune disease such as rheumatoid arthritis. Once lung scarring occurs, it is generally irreversible.

PPFs are composed of idiopathic interstitial pneumonia such as non-specific interstitial pneumonia and unclassifiable interstitial pneumonia and inhalation lung diseases such as chronic hypersensitivity pneumonia and connective tissue disease-associated ILD such as rheumatoid arthritis-related ILD and SSc-related ILD and sarcoidosis and so on. Many interstitial lung diseases (ILDs) are characterized by chronic progressive fibrosis.

 Progressive Pulmonary Fibrosis Interstitial Lung Disease Epidemiological Insights:

• In the assessment done by DelveInsight, the estimated total diagnosed prevalent cases of Interstitial Lung disease (ILD) in the 7MM were  894,597 in 2021. Out of these, around 127,754 cases were estimated to be of Progressive pulmonary fibrosis (PPF) in the 7MM.

• The United States showed the highest diagnosed prevalent cases of ILD compared to the other 7MM countries. In 2021, the total number of diagnosed prevalent cases of ILD in the US was  487,213 which is anticipated to increase by 2032. This formed around 54% of the total diagnosed prevalent cases of ILD in the 7MM.

• In the EU5, the total diagnosed prevalent cases of PPF in 2021 were 45,802 which is expected to increase considerably in the forecast time period (2022-2032). On other hand, among the 7MM (US, EU5, Japan), Japan accounted for  10,296 which is expected to decrease during the forecasted period.

• Interstitial Lung Disease (ILD) cases are categorized into various types- Idiopathic Interstitial Pneumonia (IIPs), Autoimmune ILDs, Hypersensitivity Pneumonitis, Sarcoidosis, and other ILDs. Among all these types IIPs contribute the highest percentage.

Progressive Pulmonary Fibrosis Interstitial Lung Disease Epidemiological Segmentation 

• Progressive Pulmonary Fibrosis Interstitial Lung Disease prevelant cases 

• Progressive Pulmonary Fibrosis Interstitial Lung Disease diagnosed cases 

• Progressive Pulmonary Fibrosis Interstitial Lung Disease type-specific cases 

Progressive Pulmonary Fibrosis Interstitial Lung Disease Outlook 

Progressive pulmonary fibrosis (PPF) consists of a diverse group of interstitial lung diseases (ILDs) characterized by a similar clinical phenotype of accelerated respiratory failure, frequent disease exacerbation, and earlier mortality.

ILD and its progressing forms form a substantial proportion of disabling chronic lung diseases leading to significant morbidity and mortality. From the current treatment market scenario, Nintedanib is the only approved treatment in the chronic fibrotic ILDs in the 7MM. Myriads of patients with PPFs are currently orphans of evidence-based treatments and are left with options of receiving corticosteroids and/or off-label immunosuppressive therapies with variable outcomes and are the mainstay of treatment in PPFs. These unmet treatment gaps accentuate the launch of emerging therapies.

Learn more by requesting for sample @ Progressive Pulmonary Fibrosis Interstitial Lung Disease Market Landscape

Progressive Pulmonary Fibrosis Interstitial Lung Disease Key Companies

• Boehringer Ingelheim

• And many others 

Table of Contents

1.  Key Insights 

2.  Report Introduction 

3.  Executive Summary of Progressive Pulmonary Fibrosis Interstitial Lung Disease Market 

4.  Disease Background and Overview

5.  Epidemiology and patient population

6.  Progressive Pulmonary Fibrosis Interstitial Lung Disease Market  Emerging Therapies

7.  Progressive Pulmonary Fibrosis Interstitial Lung DiseaseMarket Outlook

8.  Market Drivers 

9.  Market Barriers 

10.  Market Access and Reimbursement of Therapies

11.  Appendix

12.  Progressive Pulmonary Fibrosis Interstitial Lung Disease Market  Report Methodology

13.  DelveInsight Capabilities

14.  Disclaimer

15.  About DelveInsight

Click here to read more about Progressive Pulmonary Fibrosis Interstitial Lung Disease Market  Market Landscape

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/